Citi Initiates 90-Day Upside Catalyst Watch on Hansoh Pharmaceutical (03692.HK) with 'Buy' Rating and HK$28.5 Target Price

According to the Zhisheng Finance APP, Citibank released a research report stating that it has initiated a 90-day upside catalyst observation period for Hansoh Pharma (03692). The bank noted that driven by robust growth in innovative drug sales, the company is expected to deliver solid performance in the second half of the year. Target price is HK$28.5, with a "Buy" rating.

The bank noted that due to the government's continued support for innovative drugs and the sales recovery brought by the healthcare anti-corruption campaign, Hansoh Pharma is expected to have high visibility in its performance for the second half of the year. Catalysts include the launch of the HS-20094 (GLP-1/GIP) Ph3 study in the second half; updated data for HS-20093 (B7-H3 ADC) in the second half; and the introduction of more clinical-stage ADC candidates in the second half.